1. Home
  2. WIX vs LQDA Comparison

WIX vs LQDA Comparison

Compare WIX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wix.com Ltd.

WIX

Wix.com Ltd.

HOLD

Current Price

$47.96

Market Cap

4.7B

Sector

Technology

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$66.11

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIX
LQDA
Founded
2006
2004
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.5B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
WIX
LQDA
Price
$47.96
$66.11
Analyst Decision
Buy
Strong Buy
Analyst Count
22
11
Target Price
$134.67
$41.00
AVG Volume (30 Days)
2.5M
1.8M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.81
EPS
N/A
0.52
Revenue
N/A
$158,320,000.00
Revenue This Year
$15.80
$278.87
Revenue Next Year
$13.21
$57.13
P/E Ratio
$28.86
$123.10
Revenue Growth
N/A
1031.18
52 Week Low
$46.90
$11.85
52 Week High
$190.92
$66.78

Technical Indicators

Market Signals
Indicator
WIX
LQDA
Relative Strength Index (RSI) 33.52 71.51
Support Level N/A $31.23
Resistance Level $93.82 N/A
Average True Range (ATR) 3.86 3.84
MACD -0.17 -0.15
Stochastic Oscillator 7.83 93.62

Price Performance

Historical Comparison
WIX
LQDA

About WIX Wix.com Ltd.

Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years it has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: